Current prospects and challenges for epilepsy gene therapy

Experimental Neurology

Volumn 244, Issue , 2013, Pages 27-35

  Weinberg, Marc S ^a   McCown, Thomas J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Adenosine; Epilepsy; Galanin; Immunity; NPY

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE KINASE; ADENOVIRUS VECTOR; ASPARTOACYLASE; BRAIN DERIVED NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR 2; GALANIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; ICP 10 PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; NEUROPEPTIDE Y; NEUROPEPTIDE Y [13-36]; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; PARVOVIRUS VECTOR; PROTEIN KINASE; SOMATOSTATIN; UNCLASSIFIED DRUG;

BRAIN REGION; DISEASE MODEL; DRUG EFFICACY; EPILEPSY; GENE EXPRESSION; GENE TARGETING; HIPPOCAMPUS; HUMAN; IMMUNITY; INFERIOR COLLICULUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRIFORM CORTEX; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; EPILEPSY; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS;

EID: 84877614816     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.10.003     Document Type: Review

References (107)

1. Abe K. Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. J. Cereb. Blood Flow Metab. 2000, 20:1393-1408.
2. Bainbridge J.W., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., Viswanathan A., Holder G.E., Stockman A., Tyler N., Petersen-Jones S., Bhattacharya S.S., Thrasher A.J., Fitzke F.W., Carter B.J., Rubin G.S., Moore A.T., Ali R.R. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 2008, 358:2231-2239.
3. Baraban S.C., Hollopeter G., Erickson J.C., Schwartzkroin P.A., Palmiter R.D. Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J. Neurosci. 1997, 17:8927-8936.
4. Boutin S., Monteilhet V., Veron P., Leborgne C., Benveniste O., Montus M.F., Masurier C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 2010, 21:704-712.
5. Bovolenta R., Zucchini S., Paradiso B., Rodi D., Merigo F., Navarro Mora G., Osculati F., Berto E., Marconi P., Marzola A., Fabene P.F., Simonato M. Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J. Neuroinflammation 2010, 7:81.
6. Brooks-Kayal A.R., Shumate M.D., Jin H., Rikhter T.Y., Coulter D.A. Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy. Nat. Med. 1998, 4:1166-1172.
7. Brooks-Kayal A.R., Shumate M.D., Jin H., Lin D.D., Rikhter T.Y., Holloway K.L., Coulter D.A. Human neuronal gamma-aminobutyric acid(A) receptors: coordinated subunit mRNA expression and functional correlates in individual dentate granule cells. J. Neurosci. 1999, 19:8312-8318.
8. Buckmaster P.S., Otero-Corchon V., Rubinstein M., Low M.J. Heightened seizure severity in somatostatin knockout mice. Epilepsy Res. 2002, 48:43-56.
9. Buhl E.H., Otis T.S., Mody I. Zinc-induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model. Science 1996, 271:369-373.
10. Cascino G.D. When drugs and surgery don't work. Epilepsia 2008, 49(Suppl. 9):79-84.
11. Castillo C.G., Mendoza S., Freed W.J., Giordano M. Intranigral transplants of immortalized GABAergic cells decrease the expression of kainic acid-induced seizures in the rat. Behav. Brain Res. 2006, 171:109-115.
12. Castillo C.G., Mendoza-Trejo S., Aguilar M.B., Freed W.J., Giordano M. Intranigral transplants of a GABAergic cell line produce long-term alleviation of established motor seizures. Behav. Brain Res. 2008, 193:17-27.
13. Chen H., McCarty D.M., Bruce A.T., Suzuki K., Suzuki K. Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus. Gene Ther. 1998, 5:50-58.
14. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275:838-841.
15. Cideciyan A.V., Hauswirth W.W., Aleman T.S., Kaushal S., Schwartz S.B., Boye S.L., Windsor E.A., Conlon T.J., Sumaroka A., Roman A.J., Byrne B.J., Jacobson S.G. Vision 1 year after gene therapy for Leber's congenital amaurosis. N. Engl. J. Med. 2009, 361:725-727.
16. Colmers W.F., Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci. 1994, 17:373-379.
17. Dragunow M., Goddard G.V. Adenosine modulation of amygdala kindling. Exp. Neurol. 1984, 84:654-665.
18. Duque S., Joussemet B., Riviere C., Marais T., Dubreil L., Douar A.M., Fyfe J., Moullier P., Colle M.A., Barkats M. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 2009, 17:1187-1196.
19. During M.J., Spencer D.D. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 1992, 32:618-624.
20. During M.J., Symes C.W., Lawlor P.A., Lin J., Dunning J., Fitzsimons H.L., Poulsen D., Leone P., Xu R., Dicker B.L., Lipski J., Young D. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000, 287:1453-1460.
21. Elliott-Hunt C.R., Marsh B., Bacon A., Pope R., Vanderplank P., Wynick D. Galanin acts as a neuroprotective factor to the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5105-5110.
22. Engel J., Levesque M.F., Shields W.D. Surgical treatment of the epilepsies: presurgical evaluation. Clin. Neurosurg. 1992, 38:514-534.
23. Erickson J.C., Clegg K.E., Palmiter R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996, 381:415-421.
24. Foti S., Haberman R.P., Samulski R.J., McCown T.J. Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Ther. 2007, 14:1534-1536.
25. Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27:59-65.
26. Galea I., Bernardes-Silva M., Forse P.A., van Rooijen N., Liblau R.S., Perry V.H. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J. Exp. Med. 2007, 204:2023-2030.
27. Gernert M., Thompson K.W., Loscher W., Tobin A.J. Genetically engineered GABA-producing cells demonstrate anticonvulsant effects and long-term transgene expression when transplanted into the central piriform cortex of rats. Exp. Neurol. 2002, 176:183-192.
28. Gibbs J.W., Shumate M.D., Coulter D.A. Differential epilepsy-associated alterations in postsynaptic GABA(A) receptor function in dentate granule and CA1 neurons. J. Neurophysiol. 1997, 77:1924-1938.
29. Gotzsche C.R., Nikitidou L., Sorensen A.T., Olesen M.V., Sorensen G., Christiansen S.H., Angehagen M., Woldbye D.P., Kokaia M. Combined gene overexpression of neuropeptide Y and its receptor Y5 in the hippocampus suppresses seizures. Neurobiol. Dis. 2011, Aug. 22 (Electronic publication ahead of print). doi:10.1016/j.nbd.2011.08.012.
30. Gray S.J., Blake B.L., Criswell H.E., Nicolson S.C., Samulski R.J., McCown T.J., Li W. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 2010, 18:570-578.
31. Gray S.J., Woodward K.T., Samulski R.J. Viral vectors and delivery strategies for CNS gene therapy. Ther. Deliv. 2010, 1:517-534.
32. Gray S.J., Foti S.B., Schwartz J.W., Bachaboina L., Taylor-Blake B., Coleman J., Ehlers M.D., Zylka M.J., McCown T.J., Samulski R.J. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 2011, 22:1143-1153.
33. Gray S.J., Matagne V., Bachaboina L., Yadav S., Ojeda S.R., Samulski R.J. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 2011, 19:1058-1069.
34. Greber S., Schwarzer C., Sperk G. Neuropeptide Y inhibits potassium-stimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br. J. Pharmacol. 1994, 113:737-740.
35. Haberman R., Criswell H., Snowdy S., Ming Z., Breese G., Samulski R., McCown T. Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity. Mol. Ther. 2002, 6:495-500.
36. Haberman R.P., Samulski R.J., McCown T.J. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat. Med. 2003, 9:1076-1080.
37. Hadaczek P., Eberling J.L., Pivirotto P., Bringas J., Forsayeth J., Bankiewicz K.S. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol. Ther. 2010, 18:1458-1461.
38. Hauser W.A. Epilepsy, Frequency, Causes, and Consequences 1990, Demos, New York.
39. Hirsch M.L., Agbandje-McKenna M., Samulski R.J. Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus. Mol. Ther. 2010, 18:6-8.
40. Hirtz D., Thurman D.J., Gwinn-Hardy K., Mohamed M., Chaudhuri A.R., Zalutsky R. How common are the "common" neurologic disorders?. Neurology 2007, 68:326-337.
41. Kalev-Zylinska M.L., Symes W., Young D., During M.J. Knockdown and overexpression of NR1 modulates NMDA receptor function. Mol. Cell. Neurosci. 2009, 41:383-396.
42. Kanter-Schlifke I., Georgievska B., Kirik D., Kokaia M. Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol. Ther. 2007, 15:1106-1113.
43. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., Bland R.J., Young D., Strybing K., Eidelberg D., During M.J. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007, 369:2097-2105.
44. Klein R.L., Meyer E.M., Peel A.L., Zolotukhin S., Meyers C., Muzyczka N., King M.A. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 1998, 150:183-194.
45. Klein R.L., Dayton R.D., Tatom J.B., Henderson K.M., Henning P.P. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol. Ther. 2008, 16:89-96.
46. Kokaia M., Holmberg K., Nanobashvili A., Xu Z.Q., Kokaia Z., Lendahl U., Hilke S., Theodorsson E., Kahl U., Bartfai T., Lindvall O., Hokfelt T. Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:14006-14011.
47. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000, 342:314-319.
48. Laing J.M., Gober M.D., Golembewski E.K., Thompson S.M., Gyure K.A., Yarowsky P.J., Aurelian L. Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice. Mol. Ther. 2006, 13:870-881.
49. Lawlor P.A., Bland R.J., Mouravlev A., Young D., During M.J. Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol. Ther. 2009, 17:1692-1702.
50. Li T., Ren G., Lusardi T., Wilz A., Lan J.Q., Iwasato T., Itohara S., Simon R.P., Boison D. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J. Clin. Invest. 2008, 118:571-582.
51. Lin E.J., Richichi C., Young D., Baer K., Vezzani A., During M.J. Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur. J. Neurosci. 2003, 18:2087-2092.
52. Lin E.J., Young D., Baer K., Herzog H., During M.J. Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice. Epilepsia 2006, 47:773-780.
53. Lin L.C., Lee W.T., Chen I.J., Yang R.C. Lower plasma neuropeptide Y level in patients with atypical febrile convulsions. Kaohsiung J. Med. Sci. 2010, 26:8-12.
54. Loscher W., Leppik I.E. Critical re-evaluation of previous preclinical strategies for the discovery and the development of new antiepileptic drugs. Epilepsy Res. 2002, 50:17-20.
55. Loscher W., Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011, 52:657-678.
56. Loscher W., Ebert U., Lehmann H., Rosenthal C., Nikkhah G. Seizure suppression in kindling epilepsy by grafts of fetal GABAergic neurons in rat substantia nigra. J. Neurosci. Res. 1998, 51:196-209.
57. Lu X., Mazarati A., Sanna P., Shinmei S., Bartfai T. Distribution and differential regulation of galanin receptor subtypes in rat brain: effects of seizure activity. Neuropeptides 2005, 39:147-152.
58. Lundstrom L., Elmquist A., Bartfai T., Langel U. Galanin and its receptors in neurological disorders. Neuromolecular Med. 2005, 7:157-180.
59. Macdonald R.L., Bianchi M.T., Feng H. Mutations linked to generalized epilepsy in humans reduce GABA(A) receptor current. Exp. Neurol. 2003, 184(Suppl. 1):S58-S67.
60. Mandel R.J., Spratt S.K., Snyder R.O., Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:14083-14088.
61. Manno C.S., Pierce G.F., Arruda V.R., Glader B., Ragni M., Rasko J.J., Ozelo M.C., Hoots K., Blatt P., Konkle B., Dake M., Kaye R., Razavi M., Zajko A., Zehnder J., Rustagi P.K., Nakai H., Chew A., Leonard D., Wright J.F., Lessard R.R., Sommer J.M., Tigges M., Sabatino D., Luk A., Jiang H., Mingozzi F., Couto L., Ertl H.C., High K.A., Kay M.A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 2006, 12:342-347.
62. Mastakov M.Y., Baer K., Symes C.W., Leichtlein C.B., Kotin R.M., During M.J. Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J. Virol. 2002, 76:8446-8454.
63. Mazarati A.M., Wasterlain C.G. Anticonvulsant effects of four neuropeptides in the rat hippocampus during self-sustaining status epilepticus. Neurosci. Lett. 2002, 331:123-127.
64. Mazarati A.M., Liu H., Soomets U., Sankar R., Shin D., Katsumori H., Langel U., Wasterlain C.G. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J. Neurosci. 1998, 18:10070-10077.
65. Mazarati A.M., Hohmann J.G., Bacon A., Liu H., Sankar R., Steiner R.A., Wynick D., Wasterlain C.G. Modulation of hippocampal excitability and seizures by galanin. J. Neurosci. 2000, 20:6276-6281.
66. McCarty D.M. Self-complementary AAV vectors; advances and applications. Mol. Ther. 2008, 16:1648-1656.
67. McCown T.J. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol. Ther. 2006, 14:63-68.
68. McCown T.J., Xiao X., Li J., Breese G.R., Samulski R.J. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 1996, 713:99-107.
69. Melander T., Kohler C., Nilsson S., Hokfelt T., Brodin E., Theodorsson E., Bartfai T. Autoradiographic quantitation and anatomical mapping of 125I-galanin binding sites in the rat central nervous system. J. Chem. Neuroanat. 1988, 1:213-233.
70. Mendell J.R., Campbell K., Rodino-Klapac L., Sahenk Z., Shilling C., Lewis S., Bowles D., Gray S., Li C., Galloway G., Malik V., Coley B., Clark K.R., Li J., Xiao X., Samulski J., McPhee S.W., Samulski R.J., Walker C.M. Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med. 2010, 363:1429-1437.
71. Moneta D., Richichi C., Aliprandi M., Dournaud P., Dutar P., Billard J.M., Carlo A.S., Viollet C., Hannon J.P., Fehlmann D., Nunn C., Hoyer D., Epelbaum J., Vezzani A. Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. Eur. J. Neurosci. 2002, 16:843-849.
72. Nathanson J.L., Yanagawa Y., Obata K., Callaway E.M. Preferential labeling of inhibitory and excitatory cortical neurons by endogenous tropism of adeno-associated virus and lentivirus vectors. Neuroscience 2009, 161:441-450.
73. Noe F., Pool A.H., Nissinen J., Gobbi M., Bland R., Rizzi M., Balducci C., Ferraguti F., Sperk G., During M.J., Pitkanen A., Vezzani A. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008, 131:1506-1515.
74. Noe F., Vaghi V., Balducci C., Fitzsimons H., Bland R., Zardoni D., Sperk G., Carli M., During M.J., Vezzani A. Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. Gene Ther. 2010, 17:643-652.
75. Nolte M.W., Loscher W., Herden C., Freed W.J., Gernert M. Benefits and risks of intranigral transplantation of GABA-producing cells subsequent to the establishment of kindling-induced seizures. Neurobiol. Dis. 2008, 31:342-354.
76. Paradiso B., Marconi P., Zucchini S., Berto E., Binaschi A., Bozac A., Buzzi A., Mazzuferi M., Magri E., Navarro Mora G., Rodi D., Su T., Volpi I., Zanetti L., Marzola A., Manservigi R., Fabene P.F., Simonato M. Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7191-7196.
77. Paradiso B., Zucchini S., Su T., Bovolenta R., Berto E., Marconi P., Marzola A., Navarro Mora G., Fabene P.F., Simonato M. Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia 2011, 52:572-578.
78. Pascual O., Casper K.B., Kubera C., Zhang J., Revilla-Sanchez R., Sul J.Y., Takano H., Moss S.J., McCarthy K., Haydon P.G. Astrocytic purinergic signaling coordinates synaptic networks. Science 2005, 310:113-116.
79. Peden C.S., Burger C., Muzyczka N., Mandel R.J. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J. Virol. 2004, 78:6344-6359.
80. Peel A.L., Klein R.L. Adeno-associated virus vectors: activity and applications in the CNS. J. Neurosci. Methods 2000, 98:95-104.
81. Qiao C., Yuan Z., Li J., He B., Zheng H., Mayer C., Xiao X. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther. 2011, 18:403-410.
82. Raol Y.H., Lund I.V., Bandyopadhyay S., Zhang G., Roberts D.S., Wolfe J.H., Russek S.J., Brooks-Kayal A.R. Enhancing GABA(A) receptor alpha 1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J. Neurosci. 2006, 26:11342-11346.
83. Richichi C., Lin E.J., Stefanin D., Colella D., Ravizza T., Grignaschi G., Veglianese P., Sperk G., During M.J., Vezzani A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 2004, 24:3051-3059.
84. Sander J.W. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993, 34:1007-1016.
85. Schinder A.F., Poo M. The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci. 2000, 23:639-645.
86. Seki T., Matsubayashi H., Amano T., Kitada K., Serikawa T., Sasa M., Sakai N. Adenoviral gene transfer of aspartoacylase ameliorates tonic convulsions of spontaneously epileptic rats. Neurochem. Int. 2004, 45:171-178.
87. Shafer P.O., Begley C. The human and economic burden of epilepsy. Epilepsy Behav. 2000, 1:91-92.
88. Shafer S.Q., Hauser W.A., Annegers J.F., Klass D.W. EEG and other early predictors of epilepsy remission: a community study. Epilepsia 1988, 29:590-600.
89. Sheikh S.P., Hakanson R., Schwartz T.W. Y1 and Y2 receptors for neuropeptide Y. FEBS Lett. 1989, 245:209-214.
90. Siegel A.M. Presurgical evaluation and surgical treatment of medically refractory epilepsy. Neurosurg. Rev. 2004, 27:1-18. discussion 19-21.
91. Simonato M., Tongiorgi E., Kokaia M. Angels and demons: neurotrophic factors and epilepsy. Trends Pharmacol. Sci. 2006, 27:631-638.
92. Skofitsch G., Sills M.A., Jacobowitz D.M. Autoradiographic distribution of 125I-galanin binding sites in the rat central nervous system. Peptides 1986, 7:1029-1042.
93. Sorensen A.T., Kanter-Schlifke I., Carli M., Balducci C., Noe F., During M.J., Vezzani A., Kokaia M. NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. Hippocampus 2008, 18:564-574.
94. Sorensen A.T., Nikitidou L., Ledri M., Lin E.J., During M.J., Kanter-Schlifke I., Kokaia M. Hippocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp. Neurol. 2009, 215:328-333.
95. Theofilas P., Brar S., Stewart K.A., Shen H.Y., Sandau U.S., Poulsen D., Boison D. Adenosine kinase as a target for therapeutic antisense strategies in epilepsy. Epilepsia 2011, 52:589-601.
96. Thoenen H., Sendtner M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. 2002, 5:1046-1050. Suppl.
97. Thompson K.W. Genetically engineered cells with regulatable GABA production can affect afterdischarges and behavioral seizures after transplantation into the dentate gyrus. Neuroscience 2005, 133:1029-1037.
98. Thompson K.W., Suchomelova L.M. Transplants of cells engineered to produce GABA suppress spontaneous seizures. Epilepsia 2004, 45:4-12.
99. Vezzani A., Sperk G. Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy?. Neuropeptides 2004, 38:245-252.
100. Weinberg M.S., Blake B.L., Samulski R.J., McCown T.J. The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5. Gene Ther. 2011, 18:961-968.
101. Woldbye D.P., Larsen P.J., Mikkelsen J.D., Klemp K., Madsen T.M., Bolwig T.G. Powerful inhibition of kainic acid seizures by neuropeptide Y via Y-5 receptors. Nat. Med. 1997, 3:761-764.
102. Woldbye D.P., Angehagen M., Gotzsche C.R., Elbrond-Bek H., Sorensen A.T., Christiansen S.H., Olesen M.V., Nikitidou L., Hansen T.V., Kanter-Schlifke I., Kokaia M. Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain 2010, 133:2778-2788.
103. Xiao X., McCown T.J., Li J., Breese G.R., Morrow A.L., Samulski R.J. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res. 1997, 756:76-83.
104. Xie J., Xie Q., Zhang H., Ameres S.L., Hung J.H., Su Q., He R., Mu X., Seher Ahmed S., Park S., Kato H., Li C., Mueller C., Mello C.C., Weng Z., Flotte T.R., Zamore P.D., Gao G. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol. Ther. 2011, 19:526-535.
105. Yoo Y.M., Lee C.J., Lee U., Kim Y.J. Neuroprotection of adenoviral-vector-mediated GDNF expression against kainic-acid-induced excitotoxicity in the rat hippocampus. Exp. Neurol. 2006, 200:407-417.
106. Zafar R., King M.A., Frazier C.J., Carney P.R. Dissecting the Role of Somatostatin as a Neuroprotective Agent 2010, Society for Neuroscience, San Diego, CA.
107. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362:299-309.